Guselkumab Improves Psoriatic Arthritis in Phase 2a Study
Guselkumab significantly improved joint symptoms, physical function, psoriasis, enthesitis, dactylitis and quality of life in patients with active psoriatic arthritis, researchers report.
Stem Cell Transplant Preferred over Cyclophosphamide for Severe Scleroderma
Myeloablative autologous hematopoietic stem cell transplantation is a superior treatment in the long term as compared to cyclophosphamide for severe scleroderma, research shows.
Voclosporin and Remission in Lupus Nephritis
The calcineurin inhibitor voclosporin has shown superior complete remission rates among lupus nephritis patients taking 23.7 mg (considered a low dose) of the drug, twice daily.
Denosumab vs. Risedronate in Glucocorticoid-Treated Patients
Denosumab significantly increased spine and hip bone mineral density as compared to risedronate in osteoporosis patients treated with glucocorticoids.
Glucocorticoid-Induced Osteoporosis Responds to Denosumab
ACR 2016: Denosumab increases spine and hip bone mineral density in glucocorticoid-induced osteoporosis.
Axial Spondyloarthritis Diagnosis Late by 10 Years
Chronic back pain may not be as it seems. Many patients suffer for years before being diagnosed with axial spondyloarthritis.
Keeping Axial Spondyloarthritis Patients from Falling Through the Cracks
In this article, we highlight a recent NEJM review that addresses the difference between axial spondyloarthritis and ankylosing spondylitis.
Value-Based Care for the High-Need Patient
Improving care for high-need, high-cost patients is an imperative for patients and the healthcare system. Programs are in development, NEJM perspective reports.
Ixekizumab Shown to Have Lasting Effects for Psoriasis
A NEJM study of three clinical trials for ixekizumab to treat mild to moderate psoriasis, shows that the IL-17A inhibitor performs well through 60 weeks.
Despite Positive Study Results, Triple Therapy Rarely Used in RA
Triple therapy in RA is infrequent, despite mounting evidence that this more cost-effective option might be as effective as treatment intensification with biologic disease-modifying antirheumatic drugs.
By clicking Accept, you agree to become a member of the UBM Medica Community.